EFFICACY AND TOLERABILITY OF MICRONEEDLING ASSISTED TOPICAL O.O25% DUTASTERIDE LOTION MESOTHERAPY IN COMPARISION WITH MICRONEEDLING ALONE FOR TREATMENT OF ANDROGENETIC ALOPECIA IN MALES ON 5% MINOXIDIL LOTION-A randomised clinical study

EFFICACY AND TOLERABILITY OF MICRONEEDLING ASSISTED TOPICAL O.O25% DUTASTERIDE LOTION MESOTHERAPY IN COMPARISION WITH MICRONEEDLING ALONE FOR TREATMENT OF ANDROGENETIC ALOPECIA IN MALES ON 5% MINOXIDIL LOTION-A randomised clinical study - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105272

Enrollment

Registered

2026-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Microneedling alone for androgenetic alopecia: microneedling procedure participants will receive Microneedling treatment from baseline followed by sessions every week for a total of 12

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age: Males aged 18 to 50 years. 2.Diagnosis of Androgenetic Alopecia: Male participants diagnosed with moderate to severe androgenetic alopecia (Norwood-Hamilton Grades 2-5). Have given written consent before any treatment is commenced.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to Dutasteride or Other 5-Alpha-Reductase Inhibitors: Participants with a known allergy or sensitivity to dutasteride or other similar medications (e.g., finasteride).. 2.Patient having keloid scaring or keloidal tendency. 3.History of bleeding disorder and anticoagulant therapy. 4.Oral steroid therapy. 5.Active skin infection like warts, herpes and bacterial infection. 6.Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results. 7.Patients having any other inflammatory conditions of the scalp. 8.Hair loss due to any other etiology- malignancy or systemic illnesses. Patients with known hypersensitivity to topical anaesthetic agents.

Design outcomes

Primary

Measure	Time frame
increase in hair density from baseline to 6 months increase in hair thickness from base line to 6 monthsTimepoint: increase in hair density from baseline to 6 months increase in hair thickness from base line to 6 months	—

Secondary

Measure	Time frame
Hair Growth Rate: Change in hair growth rate (mm/month) from baseline to 6 months. 2. Anagen/Telogen Ratio: Change in anagen/telogen ratio from baseline to 6 months. 3. Patient-Reported Outcomes: Changes in patient-reported outcomes, such as hair growth satisfaction, hair loss severity, and quality of life.Timepoint:	—

Countries

India

Contacts

Public ContactBalkrishna Nikam

krishna vishwavidyapeeth karad

mangeshnikam@yahoo.com8275061393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026